Purple Biotech Achieves Commercially Viable Yield for IM1240 Tri-Specific Antibody.

Purple Biotech achieved commercially viable yields for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4. The achievement validates the scalability of the CAPTN-3 platform and positions the program competitively for future development. IM1240 is advancing toward first-in-human clinical trials, with an IND submission planned for 2026.